Purpose of this Study
We are doing the study to understand how your body reacts to the study drug, Cemiplimab.
Who Can Participate?
Eligibility
Adults with Squamous Cell Carcinoma that keeps coming back.
-The lesion must be about a half inch to one inch across
-The lesion must be about a half inch to one inch across
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to be in this study, you will:
-Get injected with the study drug (Cemiplimab) for 12 weeks
-Have a Blood draw
-Get a small biopsy of the skin
-Have an x-ray of your chest
-Give a urine sample
-Get injected with the study drug (Cemiplimab) for 12 weeks
-Have a Blood draw
-Get a small biopsy of the skin
-Have an x-ray of your chest
-Give a urine sample
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma ( BCC)
Principal Investigator
Meenal
Kheterpal
Protocol Number
PRO00101552
NCT ID
NCT03889912
Phase
I
Enrollment Status
OPEN TO ACCRUAL